An 8-week randomized, double-blind, placebo-controlled factorial study to evaluate the efficacy and safety of LCZ696 alone and in combination with amlodipine in patients with essential hypertension

ovartis Farmacéutica S. A0 个研究点目标入组 1,386 人开始时间: 2013年7月12日最近更新: 2014年8月5日

研究概览

暂无简介。

•1.Male or female outpatients.
•2.Patients with mild-to- moderate hypertension, untreated or currently taking antihypertensive therapy.
•3.Treated patients (using antihypertensive treatments within 4 weeks prior to Visit 1)
•must have an msSBP ?150 mmHg and<180 mmHg at the randomization visit and msSBP ?140 mmHg <180 mmHg at the preceding visit.
•4.Untreated patients (newly diagnosed with essential hypertension or having a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to Visit 1) must have an msSBP? 150 mmHg and <180 mmHg at both the randomization visit and the preceding visit.
•5.Patients must have an absolute difference of ?15 mmHg in msSBP between the randomization visit and the preceding visit.
•6.Ability to communicate and comply with all study requirements and demonstrate good medication compliance (? 80% compliance rate) during the treatment run-in period.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 1100
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 286

•1.Severe hypertension (msDBP ?110 mmHg and/or msSBP ? 180 mmHg).
•2.History of angioedema, drug- related or otherwise.
•3.History or evidence of a secondary form of hypertension, including but not limited to any of the following: renal parenchymal hypertension, renovascular hypertension (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, Cushing?s disease, pheochromocytoma, polycystic kidney disease, and drug- induced hypertension.
•4.Transient ischemic cerebral attack (TIA) during the 12 months prior to Visit 1 or any history of stroke.
•5.History of myocardial infarction, coronary bypass surgery or any percutaneous coronary intervention (PCI) during the 12 months prior to Visit 1.
•6.Pregnant or lactating women.
•7.Women of child-bearing potential not using highly effective methods of contraception.

发起方

ovartis Farmacéutica S. A